MetVital, Inc. – Pharmaceutical Development of Oxaloacetate

Modification of Cellular Metabolism to Ameliorate Disease

MetVital is a clinical-stage, metabolic therapy company developing first-in-class, broadly applicable methods to improve cellular metabolism in diseases including Glioblastoma (brain cancer), Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease.

Glutamate Excitotoxicity Kills Brain Cells

We’re working on drugs that will help eliminate Excitotoxicity

Excess free glutamate in the brain causes “Excitotoxicity” which kills brain cells.

Excitotoxicity is a serious underlying condition in Brain Cancer, Epilepsy, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Closed Head Injury and Stroke.

MetVital has developed a patented small molecule “AEO” that binds up glutamate in the bloodstream.

This causes a molecular imbalance, forcing the brain to excrete glutamate across the blood-brain barrier, and lower free brain glutamate. The lower glutamate levels protect the brain from excitotoxicity without causing side-effects in animal models.

MetVital is conducting clinical trials to develop AEO as a potential drug for a variety of brain conditions.